As expected , the FDA designates Gilead Sciences’ (NASDAQ:GILD)
remdesivir an Orphan Drug for the treatment of COVID-19. Among the
benefits of Orphan Drug status in the U.S. is a seven-year period of
market exclusivity for the indication, if approved.
Remdesivir (GS-5734), a nucleotide prodrug that
blocks a key enzyme needed for viral replication, is also being
developed for Ebola virus disease.
Shares up 2% after hours
https://seekingalpha.com/news/3554448-gileads-remdesivir-wins-orphan-drug-status-for-coronavirus
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.